Pronounced /ree-AH-tah/
Reata Pharmaceuticals, Inc. (Nasdaq:RETA) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Company’s Keywords:
biotechnology, life sciences, biopharmaceuticals, research, clinical operations
330
pharmaceuticals
11460000
NetSuite, Outlook, Microsoft Office 365, Zendesk, CloudFlare Hosting, Drupal, CloudFlare, WP Engine, Google Font API, OpenTracker, New Relic, BugHerd, Bootstrap Framework, Mobile Friendly, Nginx, Google Tag Manager, Google Analytics, ON24, WordPress.org, UltiPro, reCAPTCHA, AddThis
2002